BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10394408)

  • 1. Prostate preservation by combined external beam and HDR brachytherapy in nodal negative prostate cancer.
    Kovács G; Galalae R; Loch T; Bertermann H; Kohr P; Schneider R; Kimming B
    Strahlenther Onkol; 1999 Jun; 175 Suppl 2():87-8. PubMed ID: 10394408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fractionated perineal high-dose-rate temporary brachytherapy combined with external beam radiation in the treatment of localized prostate cancer: is lymph node sampling necessary?
    Kovács G; Galalae R
    Cancer Radiother; 2003 Apr; 7(2):100-6. PubMed ID: 12719039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer.
    Galalae RM; Kovács G; Schultze J; Loch T; Rzehak P; Wilhelm R; Bertermann H; Buschbeck B; Kohr P; Kimmig B
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):81-90. PubMed ID: 11777625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [High dosage brachytherapy and external irradiation of localized prostate carcinoma--results at the Kiel University Clinic].
    Kovács G; Galalae R; Loch T; Rzehak P; Wilhelm R; Bertermann H; Nürnberg N; Kohr P; Kimmig B
    Praxis (Bern 1994); 2001 Sep; 90(38):1617-22. PubMed ID: 11675914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose rate interstitial with external beam irradiation for localized prostate cancer--results of a prospective trial.
    Dinges S; Deger S; Koswig S; Boehmer D; Schnorr D; Wiegel T; Loening SA; Dietel M; Hinkelbein W; Budach V
    Radiother Oncol; 1998 Aug; 48(2):197-202. PubMed ID: 9783892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients.
    Kovács G; Müller K; Soror T; Melchert C; Guo X; Jocham D; Merseburger A
    Brachytherapy; 2017; 16(2):277-281. PubMed ID: 27964906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
    Makino T; Mizokami A; Namiki M
    Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer - a benchmark for high-tech external beam radiotherapy alone?
    Galalae RM; Zakikhany NH; Geiger F; Siebert FA; Bockelmann G; Schultze J; Kimmig B
    Brachytherapy; 2014; 13(2):117-22. PubMed ID: 24360880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
    Deger S; Boehmer D; Roigas J; Schink T; Wernecke KD; Wiegel T; Hinkelbein W; Budach V; Loening SA
    Eur Urol; 2005 Apr; 47(4):441-8. PubMed ID: 15774239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
    Aluwini S; van Rooij PH; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1480-5. PubMed ID: 22285661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
    Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R; Gides D; Horriot R
    Int J Med Sci; 2008 Jun; 5(3):113-20. PubMed ID: 18566673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
    Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
    Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
    Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
    Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
    Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interstitial high dosage irradiation of prostate carcinoma].
    Kovács G
    Ther Umsch; 1998 Jul; 55(7):429-31. PubMed ID: 9702111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose brachytherapy (real time) in patients with intermediate- or high-risk prostate cancer: technical description and preliminary experience.
    Prada Gómez PJ; de la Rua Calderón A; Romo Fonseca I; Evia Suárez M; Abascal García JM; Juan Rijo G; Fernández García J; González Sancho JM; Abascal García R; Rodríguez-Fernández R
    Clin Transl Oncol; 2005 Oct; 7(9):389-97. PubMed ID: 16238973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.